Cefditoren in vitro activity and spectrum: A review of international studies using reference methods

Diagnostic Microbiology and Infectious Disease

Volumn 41, Issue 1-2, 2001, Pages 1-14

  Jones, Ronald N ^a,b   Pfaller, Michael A ^c   Jacobs, Michael R ^d   Appelbaum, Peter C ^e   Fuchs, Peter C ^f  

^a Jones Group   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^f CLINICAL MICROBIOLOGY INSTITUTE   (United States)

Author keywords

Cefditoren; H. influenzae; M. catarrhalis; Orally administered lactams; Respiratory tract infections; S. pneumoniae

Indexed keywords

AMOXICILLIN; AMPICILLIN; BETA LACTAMASE; CEFACLOR; CEFDITOREN; CEFIXIME; CEFPROZIL; CEFTIBUTEN; CEFUROXIME AXETIL; CLAVULANIC ACID; DRUG BINDING PROTEIN; OXACILLIN;

ACCURACY; ANTIBIOTIC SENSITIVITY; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; BETA HEMOLYTIC STREPTOCOCCUS; COMMUNICABLE DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENTEROBACTERIACEAE; ENZYME STABILITY; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN TARGETING; RESPIRATORY TRACT INFECTION; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

CEPHALOSPORINS; COMMUNITY-ACQUIRED INFECTIONS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS;

EID: 0034778638     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0732-8893(01)00274-7     Document Type: Article

References (44)

1. In vitro activities of 22 β-lactam antibiotics against penicillin-resistant and penicillin-susceptible viridans group streptococci isolated from blood
2. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: Increasing importance of the intensive care unit
3. Novelties in the field of anti-infectives in 1998
4. In vitro activity of a new cephalosporin ME-1206 compared with other agents
5. Efficacy of cefditoren pivoxil verus amoxicilin/clavulanate in acute maxillary sinusitis
6. In vivo pharmacodynamic activity of cefditoren against Streptococcus pneumoniae
7. Interaction of penicillin binding proteins from Staphylococcus pneumoniae with cefditoren, amoxicillin and penicillin
8. In vitro study of the postantibiotic effect and the bactericidal activity of cefditoren and ten other oral antimicrobial agents against upper and lower respiratory tract pathogens
9. An in vitro characterization of cefditoren, a new oral cephalosporin
10. In vitro activity of cefditoren against clinical isolates of penicillin-susceptible and resistant strains of Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis
11. Susceptibility of Streptococcus pneumoniae and Haemophilus influenzae to cefditoren, and provisional interpretive criteria
12. Antibiotic prescribing for adults with colds, upper respiratory tract infections, and bronchitis by ambulatory care physicians
13. Cefditoren is safe and effective treatment for streptococcal pharyngitis
14. In vitro and in vivo antibacterial activity of ME 1207, a new oral cephem antibiotic
15. Effectiveness of cefditoren pivoxil in various types of uncomplicated skin and skin structure infections
16. Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species
17. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients
18. In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1,249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae
19. Cefditoren activity against nearly 1000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods
20. Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
21. In vitro and in vivo antibacterial activity of ME 1207, a new oral cephalosporin
22. Comparison of agar dilution, microdilution, Etest, and disk diffusion methods for testing activity of cefditoren against Streptococcus pneumoniae
23. Phase I clinical trial of cefditoren pivoxil (ME 1207): Pharmacokinetics in healthy volunteers
24. In vitro antibacterial activity of ME1207, a new oral cephalosporin
25. In vitro and in vivo antibacterial activity of ME 1207, a new oral cephem antibiotic
26. Bacterial pathogens isolated from patients with blood stream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
27. Synthesis and oral activity of ME 1207, a new orally active cephalosporin
28. Phase I clinical studies on a novel oral cephem antibiotic, ME1207
29. Antibacterial activity, bactericidal effect and β-lactamase stability of cefditoren, and its binding affinity to PBPs against clinical isolate of Haemophilus influenzae
30. Inoculum and bactericidal activity of cefditoren and other antibiotics against Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis
31. Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other β-lactams
32. Clinical efficacy in pediatric sinusitis infections of cefditoren pivoxil granule therapy and its in vitro antibacterial activity against clinically isolated strains
33. Efficacy of cefditoren pivoxil in the treatment of acute otitis media due to benzylpenicillin-insensitive Streptococcus pneumoniae
34. Cefditoren pivoxil, a new oral cephalosporin with in vitro bactericidal activity against Streptococcus pneumoniae at concentrations simulating human blood levels
35. Causative organisms of acute otitis media and acute sinusitis in children and their susceptibility of oral β-lactam antibiotics
36. Antibacterial activity and bactericidal effect of ME 1207, and its binding affinity to PBPs
37. In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin
38. Quality control parameters for cefditoren susceptibility tests
39. Safety and efficacy of cefditoren in acute exacerbation of chronic bronchitis
40. In vitro and in vivo antibacterial activities of CS-834, a new oral carbapenem